Quantum Immunologics Achieves Major Funding In Support Of Ongoing FDA Trials

Main Category: Breast Cancer
Also Included In: Regulatory Affairs / Drug Approvals;  Clinical Trials / Drug Trials;  Cancer / Oncology
Article Date: 17 Jul 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, is pleased to announce that it is receiving equity funding from Mentor Capital, Inc. (PINKSHEETS: MNTR) to support its FDA authorized Phase I/II trials on metastatic breast cancer, which are now underway (NCT00879489).

QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs oncofetal antigen ("OFA") to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

In addition to providing $2.2 Million in funding to help support the FDA trials through approximately February 2010, Mentor Capital has agreed to assist QI in funding future strategic stock or cash acquisitions. Mentor will also stand by as a preferred funding source for QI during later stage or additional trials.

Comprehensive information on Mentor Capital, including capital structure detail, can be found at: www.MentorCapital.com.

Source
Quantum Immunologics

• Additional
• References
• Citations